Dominari (NASDAQ:DOMH – Get Rating) is one of 44 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare Dominari to related companies based on the strength of its dividends, risk, analyst recommendations, institutional ownership, valuation, earnings and profitability.
Volatility & Risk
Dominari has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Dominari’s competitors have a beta of 4.90, meaning that their average share price is 390% more volatile than the S&P 500.
This table compares Dominari and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Commercial physical research” companies have a potential upside of 18.08%. Given Dominari’s competitors higher probable upside, analysts clearly believe Dominari has less favorable growth aspects than its competitors.
Earnings & Valuation
This table compares Dominari and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Dominari Competitors||$1.53 billion||$80.65 million||-14.31|
Dominari’s competitors have higher revenue and earnings than Dominari. Dominari is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
10.9% of Dominari shares are owned by institutional investors. Comparatively, 56.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 8.6% of Dominari shares are owned by insiders. Comparatively, 12.5% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Dominari competitors beat Dominari on 8 of the 9 factors compared.
Dominari Holdings, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.